How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

507 results for

Dysuria in Children

Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Guideline for consultations requiring sexual history taking

sexual contact (LSC) and number of partners in the last three months Gender of partner(s), anatomic sites of exposure, condom use and any suspected infection, infection risk or symptoms in partners Previous STIs For women: last menstrual period (LMP), contraceptive and cervical cytology history. Blood borne virus risk assessment and vaccination history for those at risk Agree the method of giving results Establish competency, safeguarding children/vulnerable adults Recommend/consider Recognition (...) , contraceptive and cervical cytology history Pregnancy and gynaecological history Blood borne virus risk assessment and vaccination history for those at risk Past medical and surgical history Medication history and history of drug allergies Agree the method of giving results Establish competency, safeguarding children/vulnerable adults Recommend/consider Recognition of gender-based violence/intimate partner violence 1 Alcohol and recreational drug history 2 1 This is a requirement in Scotland

2013 British Association for Sexual Health and HIV

162. Adult Urodynamics: AUA/SUFU Guideline

and significant source of impaired quality of life and comorbidity in large numbers of adults and children. Commonly, patients presenting with LUTS have overlapping symptoms and conditions, making an isolated or homogeneous source of symptoms rare. Clinicians evaluating these disorders collectively utilize history, physical examination, questionnaires and pad testing data in the evaluation of symptoms. Urodynamics (UDS) is the dynamic study of the transport, storage and evacuation of urine. UDS

2012 Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction

163. Adult Urodynamics: AUA/SUFU Guideline

is present. ( Option ; Evidence Quality: Grade C ) 19. Clinicians may perform videourodynamics in properly selected patients to localize the level of obstruction, particularly for the diagnosis of primary bladder neck obstruction. (Expert Opinion) Purpose Lower urinary tract symptoms (LUTS), which include urinary incontinence, are a common and significant source of impaired quality of life and comorbidity in large numbers of adults and children. Commonly, patients presenting with LUTS have overlapping

2012 American Urological Association

164. Monitoring of Nonsteroidal Immunosuppressive Drugs in Patients With Lung Disease and Lung Transplant Recipients

: 10.1378/chest.12-1044 Downloaded From: by David Kinnison on 11/09/ CHEST / 142 / 5 / NOVEMBER 2012 e3S in addition to normal intake in adults; additional volume given to children needs to be calculated on the basis of body weight) on the days of therapy is recommended (Grade 1C) . 3.5e. For patients who undergo or have under- gone cyclophosphamide therapy and develop hematuria, further evaluation is recommended (Grade 1B (...) was assigned one primary and one secondary author. In addi- tion, a pediatric expert provided input to sections that were relevant to children’s health care. A ? nal meeting was con- vened with the committee members to review and approve the recommendations. 1.2 Con? ict of Interest From the outset, each member completed a con? ict of interest (COI) form to be kept on ? le with ACCP. In addition, panel members updated COI forms at the face- to-face meeting and verbally related any changes in con- ? ict

2012 American College of Chest Physicians

165. Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours

: January 14, 2019 See Sponsor: Great Ormond Street Hospital for Children NHS Foundation Trust Collaborator: AstraZeneca Information provided by (Responsible Party): Great Ormond Street Hospital for Children NHS Foundation Trust Study Details Study Description Go to Brief Summary: Phase I and II study of the MEK inhibitor Selumetinib given twice daily on 5 out of 7 days in children with NF1 and inoperable plexiform neurofibromas or progressive/relapsed optic pathway gliomas. This study will test (...) the early and late toxicities of selumetinib when it is given in this intermittent schedule (in 5 out of 7 days) and will also test the effectiveness of the drug in reducing the size of plexiform neurofibromas and optic pathway gliomas in children with NF1. It will also test the effectiveness of the drug in improving the participants function in day to day life. Condition or disease Intervention/treatment Phase Neurofibromatosis Type 1 Plexiform Neurofibroma Optic Nerve Glioma Drug: Selumetinib Phase 1

2017 Clinical Trials

166. Studying the Impact of Exercise on Hot Flashes

and children will not be included. Have current history of fever, cough, dysuria or diarrhea (i.e., signs of infection). Have >10% of hot flashes predictably related to certain food ingestion alcohol intake. Have a history of "easily blushing" and have >10% hot flashes associated with embarrassing events or migraines. Have an MI, stroke, functional decline within 1 month. Have a history of somatoform disorder. Have an estimated creatinine clearance < 60ml/min. Fail to record data in the diary for >3 days

2017 Clinical Trials

167. Late Effects of Treatment for Childhood Cancer (PDQ®): Health Professional Version

for Childhood Cancer During the past five decades, dramatic progress has been made in the development of curative therapy for pediatric malignancies. Long-term survival into adulthood is the expectation for more than 80% of children with access to contemporary therapies for pediatric malignancies.[ , ] The therapy responsible for this survival can also produce adverse long-term health-related outcomes, referred to as late effects , which manifest months to years after completion of cancer treatment (...) to Support Survivor Care Risk-based screening The need for long-term follow-up for childhood cancer survivors is supported by the American Society of Pediatric Hematology/Oncology, the International Society of Pediatric Oncology, the American Academy of Pediatrics, the Children’s Oncology Group (COG), and the Institute of Medicine. A risk-based medical follow-up is recommended, which includes a systematic plan for lifelong screening, surveillance, and prevention that incorporates risk estimates based

2016 PDQ - NCI's Comprehensive Cancer Database

169. Methylthioninium chloride Proveblue

granted by: United Kingdom - Marketing authorisation number: PL 00156/0039 Differences compared to the reference medicinal product: change in therapeutic indication (to extend the indication to the treatment of chemical products-induced methaemoglobinaemia and to the use in children) and change in strength (quantitative change to the active substance). The application submitted is composed of administrative information, complete quality data, non- clinical and clinical data based on bibliographic (...) literature substituting all non-clinical tests and clinical studies. The applicant applied for the following indication: Treatment of medicinal and chemical products- induced methaemoglobinaemia. Methylthioninium chloride Proveblue is indicated in adults and children above the age of 3 months. Page 4/47 Information on Paediatric requirements Not applicable Scientific Advice: The applicant received Scientific Advice from the CHMP on 25 June 2009. The Scientific Advice pertained to non-clinical

2011 European Medicines Agency - EPARs

170. Jevtana - cabazitaxel

related to body surface area and tumour type. Elderly In the population pharmacokinetic analysis in 70 patients of 65 years and older (57 from 65 to 75 and 13 patients above 75), no age effect on the pharmacokinetics of cabazitaxel was observed. CHMP assessment report EMA/CHMP/782336/2010 Page 32/66 Paediatric patients Safety and effectiveness of JEVTANA have not been established in children and adolescents below 18 years of age. Hepatic impairment No formal studies in patients with hepatic impairment

2011 European Medicines Agency - EPARs

171. Icatibant (Firazyr)

times/day, then decrease by = 50% every = 1-3 month (may increase by = 200 mg if attack occurs) *Labeling states safety and efficacy in children 0 to 12 years of age have not been established; **Labeling states safety and effectiveness not established in neonates, infants, or children, with three subjects studied under the age of 18 years in single efficacy trial; IV = intravenous; SC = subcutaneous Of note, severe hypersensitivity reactions, including anaphylaxis, are listed in the Warnings

2011 FDA - Drug Approval Package

172. Ezogabine (Potiga)

events of dysuria. These events occurred in healthy volunteers and are consistent with prior observations in ezogabine treatment but also demonstrate the events of voiding dysfunction are not restricted to the epilepsy population. Psychotic symptoms: Two patients in the open label extension studies had SAEs due to psychotic symptoms, in one patient there was a positive dechallenge. In the clinical pharmacology studies one healthy control subject had an SAE due to psychotic symptoms (covered fully

2011 FDA - Drug Approval Package

174. Guidance on adolescent sexual health

and Westminster Hospital NHS Foundation Trust, Imperial, London, Consultant GUM / HIV • Rita Browne – Haringey NHS Trust Consultant GUM / HIV. BASHH Adolescent Special Interest Group (ASIG) • Caroline Foster –Imperial College Healthcare NHS Trust, London Consultant Paediatrician HIV • Eva Jungmann – Archway Sexual Health, Camden Primary Care Trust, London, Consultant GUM / HIV • Elaine Pearson Scott – Positive Parenting Children (PPC) (Lambeth) • Maria Phelan – Children and Young people HIV Network (...) Coordinator, National Children’s Bureau 5 • Katia Prime – St George’s Hospital NHS Trust, London, Consultant GUM / HIV • Ella Sherlock – Clinical Psychologist HIV Child and Family Psychology Service CASCAID (Lewisham and Southwark), Paediatric HIV Psychology Group • Rebecca Wilkins – Community Matron, Diabetes Centre Newbury park Redbridge PCT 1.2 Competing Interests None declared 1.3 Stakeholder involvement HIV Young Persons’ Network (HYPNET) - Caroline Foster - Chair Children’s HIV Association (CHIVA

2011 The Children's HIV Association

175. Child maltreatment: when to suspect maltreatment in under 16s

30 2.5 Recurrent abdominal pain 30 More information 30 Update information 31 Child maltreatment: when to suspect maltreatment in under 18s (CG89) © NICE 2019. All rights reserved. Subject to Notice of rights ( conditions#notice-of-rights). Page 3 of 32Ov Overview erview This guideline covers the signs of possible child maltreatment in children and young people aged under 18 years. It aims to raise awareness and help health professionals who are not child (...) features) that may be observed when a child presents to healthcare professionals. Its purpose is to raise awareness and help healthcare professionals who are not specialists in child protection to identify children who may be being maltreated. It does not give healthcare professionals recommendations on how to diagnose, confirm or disprove child maltreatment. Children may present with both physical and psychological symptoms and signs that constitute alerting features of one or more types

2009 National Institute for Health and Clinical Excellence - Clinical Guidelines

176. UTI: More than you ever wanted to know

on diagnosis of UTI is very difficult to interpret. Because, what is the definition of a UTI? It’s not consistent across studies. There is no clear gold standard. It is often defined based on a culture, although a positive culture has many different definitions as well. Unfortunately, we know that people, especially children and the elderly, can have positive urine cultures without having UTIs. UTIs also occur without a positive culture. So culture both over and under calls UTI and can’t be used as a true (...) . History and Physical Self diagnosis is pretty accurate. If a woman has had a previous UTI and now has similar symptoms, that has a positive LR of 4.0 and is about 90% accurate for UTI. (Lane 2011; Bent 2002) A women telling you that she has a UTI is just as accurate as a positive dipstick (both with positive likelihood ratios of 4). (Aubin 2007) It’s not clear if these two pieces of information are additive, but there is reason to think they wouldn’t be: women without typical symptoms such as dysuria

2017 First10EM

178. Tepadina - thiotepa

(Gutierrez-Delgado, 2003; Gutierrez-Delgado, 2001) makes high dose thiotepa one of the first drugs used in this context in pre-irradiated or very young children. A broad base of clinical experience with thiotepa and different combination partners in multiple complex contexts is available. Thiotepa can certainly be regarded as well established and systematically used in the dose-intensive treatment of paediatric brain tumours. Thiotepa is covering all patient ages, from pediatric to elderly, giving

2010 European Medicines Agency - EPARs

179. Surgical Complications Following Early Genitourinary Reconstructive Surgery for Congenital Adrenal Hyperplasia- Interim Analysis at 6 Years. (PubMed)

patients from April 2003 to April 2015 who underwent genitourinary reconstructive surgeries. Demographic data and surgical postoperative complications (per Unplanned Postoperative Morbidity in Children [UPMC] and Clavien-Dindo classification) were evaluated.The average age at the time primary surgery was done at our institute was 17 ± 20 (5-87) months; the average length of follow-up was 72.56 ± 36.95 (4.5-142) months. The average length of the common urogenital sinus was 4.5 ± 1.9 (2.5-6.4) cm, and 15 (...) out of 22 (68%) patients had high confluence. A total of 7 complications were observed in 7 (27%) patients, 3 patients had Clavien grade I and UPMC 0 (dysuria, stitch dehiscence, wound separation), and 2 had Clavien grade II and UPMC 1 (urinary tract infection). Two (7.6%) patients required revision surgery, and both of them had Clavien grade IIIB. One patient had UPMC score 5 (suprapubic tube insertion for urinary retention secondary to cicatrization of the surgical site).Genitourinary

2016 Urology

180. Milnacipran Pierre Fabre Medicament

studies have not been performed. The use of milnacipran in children is therefore not supported by any juvenile toxicity studies. • Toxicokinetic data Toxicokinetic data for milnacipran racemate are available for all animal species investigated. Toxicokinetic studies differentiating between the single enantiomers have only been performed for the rat. Milnacipran did not accumulate following repeated oral administration in animal species investigated. No clear gender effect was observed in nonclinical

2010 European Medicines Agency - EPARs

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>